Curative Biotechnology, Inc. (CUBT)
OTC Markets OTCID
Price as at 30 Sept 2026, 17:23 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Curative Biotechnology, Inc. trades at $0.93. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Curative Biotechnology, Inc.
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying a cytotoxic drug conjugate directly to the tumor site to kill the tumor by inhibiting tumor growth and migration of the tumor. The company has a licensing and co-development agreement with Mid-Atlantic BioTherapeutics, Inc. to develop IMT504 to treat late-stage rabies and COVID-19 vaccine; and development agreement with the University of Pennsylvania School of Veterinary Medicine for the development of a metformin-based ophthalmic formulation. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Palm Beach Gardens, Florida.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its CUBT data?
Fundamentals for CUBT come from company filings and exchange data, as listed on OTC Markets OTCID; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 17:23 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for CUBT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.